GlassScriptPhysician profile
Brittany Cogan
NPI 1134880198
$1,922.80
in general payments reported to CMS, 2019-2025
32 companies · $985 in 2025
The $985 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $316 · 2024: $622 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.24 | 2024-2025 | |
| Pfizer INC. | $178.52 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.35 | 2022-2024 | Jardiance |
| Corium, LLC | $130.37 | 2022 | |
| Novo Nordisk INC | $117.61 | 2024-2025 | Wegovy |
| Lilly USA, LLC | $94.08 | 2024-2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $88.71 | 2022-2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $85.65 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $76.71 | 2024-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $68.85 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.70 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $62.11 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $54.16 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $52.58 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $46.91 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $38.77 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $38.47 | 2024 | Glassia |
| Sumitomo Pharma America, INC. | $38.25 | 2025 | Gemtesa |
| Viatris Specialty LLC | $35.73 | 2025 | Yupelri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.27 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.74 | 2025 | Xifaxan |
| Ardelyx, INC. | $24.20 | 2025 | Ibsrela |
| Sonex Health, INC. | $23.92 | 2025 | Sx-One Microknife |
| Mylan Specialty L.P. | $18.89 | 2024 | Yupelri |
| Lundbeck LLC | $18.59 | 2024 | Rexulti |
| Verona Pharma, INC. | $18.32 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $17.51 | 2024 | Xarelto |
| Ucb, INC. | $17.41 | 2024 | Nayzilam |
| Corcept Therapeutics | $16.98 | 2025 | Korlym |
| Abbott Laboratories | $16.77 | 2025 | Freestyle Libre 3 |
| Lantheus Medical Imaging, INC. | $14.73 | 2022 | |
| Sanofi Pasteur INC. | $14.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Cogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.